Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

NCT04561518 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT04561518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04561518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Lead sponsor
Alnylam Pharmaceuticals
Phase
Observational
Overall status
Recruiting
Start date
November 23, 2020
Completion date
December 31, 2033
Enrollment
1,500 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

attr amyloidosis, transthyretin-mediated amyloidosis